TELA Bio, Inc. current report, 07 May 2021

TELA Bio, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by TELA Bio, Inc. on May 7, 2021, with the earliest event reported on that date. The filing primarily addresses executive leadership changes and references the announcement of financial results for the first quarter ended March 31, 2021, which was issued via press release on May 13, 2021.

Key Financial Metrics

The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not detailed in the body of this 8-K.

Material Changes

  • Executive Departure: Nora Brennan, Chief Financial Officer, resigned effective June 4, 2021, to pursue another opportunity.
  • Interim Appointment: Megan Smeykal, Vice President and Corporate Controller, will assume the duties of principal financial officer on an interim basis until a permanent CFO is appointed.
  • Investor Relations Update: The company updated its corporate slide deck for investor meetings, furnished as Exhibit 99.2.

Guidance, Outlook, and Risks

The filing does not contain specific forward-looking guidance, management commentary on financial performance, or a detailed discussion of risks and contingencies within the text provided. The company noted that the information in the press release and slide deck is not deemed "filed" for purposes of Section 18 of the Exchange Act.

Key Facts for Investor Verification

  • Verify the specific Q1 2021 financial results (revenue, net loss, cash position) in the press release dated May 13, 2021 (Exhibit 99.1).
  • Confirm the timeline for the appointment of a permanent Chief Financial Officer following the interim arrangement.
  • Review the updated corporate slide deck (Exhibit 99.2) for any changes to the company's strategic outlook or pipeline status.
  • Note that the interim CFO, Megan Smeykal, has no family relationships with directors or officers and no undisclosed compensatory arrangements.